WebPatients receiving Zortress may require dose adjustments based on everolimus blood concentrations achieved, tolerability, individual response, change in concomitant medications and the clinical situation. Optimally, dose adjustments of Zortress should be based on trough concentrations obtained 4 or 5 days after a previous dosing change. WebZortress is an immunosuppressant. It works by blocking the action of certain blood cells in the immune system that may cause the body to reject the transplanted organ. Important safety information: Zortress may cause dizziness or drowsiness. This effect may be worse if you take it with alcohol or certain medicines. Use Zortress with caution.
MEDICATION GUIDE - Novartis
WebAug 23, 2024 · Zortress (everolimus) is a macrolide immunosuppressant used to prevent organ rejection after a kidney or liver transplant. Zortress is used together with … Webdiabetes. heart disease. high cholesterol. immune system problems. infection (especially a virus infection such as chickenpox, cold sores, or herpes) kidney disease. liver disease. low blood counts, like low white cell, platelet, or red cell counts. recent or ongoing radiation. dick\u0027s water shoes
WARNING: IMMUNOSUPPRESSION AND RENAL FUNCTION …
WebSPL UNCLASSIFIED SECTION. Drug Facts. Active ingredient (in each tablet) Cetirizine HCl 10 mg. Purpose. Antihistamine. Uses. temporarily relieves these symptoms due to hay fever or other upper respiratory allergies: runny nose - sneezing - itchy, watery eyes - itching of the nose or throat. Warnings. • Zortress is an mTOR inhibitor immunosuppressant indicated for the prophylaxis of organ rejection in adult patients: • Kidney Transplant: at low-moderate immunologic risk. Use in combination with basiliximab, cyclosporine (reduced doses) and corticosteroids • Liver Transplant: Administer no earlier than 30 days posttransplant. Use in combination with tacrolimus (reduced doses) and ... WebAug 23, 2024 · The data described below reflect exposure to Zortress in an open-label, randomized trial of de novo kidney transplant patients of concentration-controlled everolimus at an initial Zortress starting dose of 1.5 mg per day [target trough concentrations 3 to 8 ng/mL with reduced exposure cyclosporine (N = 274) compared to mycophenolic acid (N ... city center development